Abstract:Despite the rapid advancement in the introduction of new drugs for cancer therapy, the frequent emergence of drug resistance leads to disease progression or tumor recurrence resulting in dismal prognosis. Given that genetic mutations are thought to be important drivers of anti-cancer drug resistance, it is of paramount importance to pin-point mutant genes that mediate drug resistance and elucidate the underlying molecular mechanisms in order to develop novel modalities to surmount chemoresistance and achieve more efficacious and durable cancer therapies. Cumulative evidence suggests that epigenetic alterations, especially those mediated by epigenetic enzymes with high mutation rates in cancer patients, can be a crucial factor in the development of chemoresistance. Mutant epigenetic enzymes have altered enzymatic activity which may directly or indirectly affect the level of histone modifications. This can change chromatin structure and function hence altering the expression of target genes and eventually lead to chemoresistance. In the current review, we summarize epigenetic enzyme mutations and the consequent mechanisms of drug resistance in pre-clinical drug-resistance models and relapsed cancer patient specimens. We also introduce previously unreported mutation sites in the DOT1 domain of DOT1L, which are related to lung cancer drug resistance. It is worth noting that mutations occur not only in domains with enzymatic activity but also in non-catalytic regions. Each protein domain is an evolutionarily conserved region with independent functional properties. This may provide a rationale for the potential development of small molecule inhibitors which target various functional domains of epigenetic enzymes. Finally, based on the multitude of mechanisms of drug resistance, we propose several therapeutic strategies to reverse or overcome drug-resistance phenotypes, with the aim to provide cancer patients with novel efficacious combination therapeutic regimens and strategies to improve patient prognosis.

[DNA Topoisomerase and Telomerase Activity with Relation to Multi-Drug Resistance in Leukemia--review].

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Reversal of Multidrug Resistance by Topoisomerase Ⅱ in Glioma

Impact of drug resistance gene on breast cancer chemotherapy

DNA damage and metabolic mechanisms of cancer drug resistance

Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review

Molecular Characteristics of Leukemia Stem Cells and Up-Dating Therapeutic Strategy

The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.

Emerging DNA topoisomerase inhibitors as anticancer drugs

Mechanism of action of DNA topoisomerase inhibitors

Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance

The mechanisms of multidrug resistance of breast cancer and research progress on related reversal agents

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets

Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy

Telomerase Inhibition in the Treatment of Leukemia: A Comprehensive Review

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents

Unravelling the role of natural and synthetic products as DNA topoisomerase inhibitors in hepatocellular carcinoma